While a four-component version of the therapy, known as AIPV, also includes an amphiphile peptide vaccine targeting tyrosinase-related protein 2 (Trp2, a melanoma antigen), we focused upon AIP in this study as it is more representative of current combination ICB therapies and does not direct the response to a particular antigen. Here, DCT is linked to melanoma.